You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNisoldipine
Accession NumberDB00401  (APRD00635)
TypeSmall Molecule
GroupsApproved
DescriptionNisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Structure
Thumb
Synonyms
isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Nisoldipin
Nisoldipina
Nisoldipine
Nisoldipino
Nisoldipinum
Sular
External Identifiers
  • Bay K 5552
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NisoldipineTablet, film coated, extended release8.5 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
NisoldipineTablet, film coated, extended release8.5 mg/1OralPrasco Laboratories2012-02-27Not applicableUs
NisoldipineTablet, film coated, extended release17 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
NisoldipineTablet, film coated, extended release17 mg/1OralPrasco Laboratories2012-02-27Not applicableUs
NisoldipineTablet, film coated, extended release25.5 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
NisoldipineTablet, film coated, extended release34 mg/1OralPrasco Laboratories2012-02-27Not applicableUs
NisoldipineTablet, film coated, extended release34 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
SularTablet, film coated, extended release34 mg/1OralShionogi Inc.1995-02-02Not applicableUs
SularTablet, film coated, extended release25.5 mg/1OralPhysicians Total Care, Inc.2009-02-24Not applicableUs
SularTablet, film coated, extended release8.5 mg/1OralShionogi Inc.1995-02-02Not applicableUs
SularTablet, film coated, extended release17 mg/1OralShionogi Inc.1995-02-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NisoldipineTablet, film coated, extended release40 mg/1OralPhysicians Total Care, Inc.2008-08-29Not applicableUs
NisoldipineTablet, film coated, extended release8.5 mg/1OralMylan Pharmaceuticals Inc.2011-01-28Not applicableUs
NisoldipineTablet, film coated, extended release20 mg/1OralMylan Pharmaceuticals Inc.2008-07-25Not applicableUs
NisoldipineTablet, film coated, extended release17 mg/1OralMylan Pharmaceuticals Inc.2011-01-28Not applicableUs
NisoldipineTablet, film coated, extended release30 mg/1OralMylan Pharmaceuticals Inc.2008-07-25Not applicableUs
NisoldipineTablet, film coated, extended release25.5 mg/1OralMylan Pharmaceuticals Inc.2011-01-28Not applicableUs
NisoldipineTablet, film coated, extended release40 mg/1OralMylan Pharmaceuticals Inc.2008-07-25Not applicableUs
NisoldipineTablet, film coated, extended release34 mg/1OralMylan Pharmaceuticals Inc.2011-01-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BaymycardBayer
Baymycard RRBayer
Bo PingRui Yang Pharm
Di Yi XinTasly
Ji Ni Le ErJiankang Pharmaceutical
NinobarucinChoseido Pharmaceutical
NisomynardYoshindo
RiohardTaiyo Pharmaceutical
RuidiNanjing Sanrui Pharmaceutical Co.
SyscorBayer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4I8HAB65SZ
CAS number63675-72-9
WeightAverage: 388.4144
Monoisotopic: 388.16343651
Chemical FormulaC20H24N2O6
InChI KeyVKQFCGNPDRICFG-UHFFFAOYSA-N
InChI
InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
IUPAC Name
3-methyl 5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C
Pharmacology
IndicationFor the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Structured Indications
PharmacodynamicsNisoldipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nisoldipine is similar to other peripheral vasodilators. Nisoldipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of actionBy deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nisoldipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent calcium channel subunit alpha-2/delta-1Proteinyes
inhibitor
HumanP54289 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinyes
inhibitor
HumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinyes
inhibitor
HumanQ13698 details
Related Articles
AbsorptionRelatively well absorbed into the systemic circulation with 87% of the radiolabeled drug recovered in urine and feces. The absolute bioavailability of nisoldipine is about 5%.
Volume of distributionNot Available
Protein binding99%
Metabolism

Pre-systemic metabolism in the gut wall, and this metabolism decreases from the proximal to the distal parts of the intestine. Nisoldipine is highly metabolized; 5 major urinary metabolites have been identified. The major biotransformation pathway appears to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, present in plasma at concentrations approximately equal to the parent compound, appears to be the only active metabolite and has about 10% of the activity of the parent compound. Cytochrome P450 enzymes are believed to play a major role in the metabolism of nisoldipine. The particular isoenzyme system responsible for its metabolism has not been identified, but other dihydropyridines are metabolized by cytochrome P450 IIIA4.

Route of eliminationAlthough 60-80% of an oral dose undergoes urinary excretion, only traces of unchanged nisoldipine are found in urine.
Half life7-12 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nisoldipine Action PathwayDrug actionSMP00381
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nisoldipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nisoldipine.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nisoldipine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Acebutolol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Nisoldipine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nisoldipine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nisoldipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nisoldipine.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Nisoldipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nisoldipine.Approved, Investigational
AlprenololNisoldipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Nisoldipine.Approved, Investigational
AmifostineNisoldipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Amiloride.Approved
AmiodaroneThe serum concentration of Nisoldipine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nisoldipine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nisoldipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nisoldipine.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nisoldipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nisoldipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Amyl Nitrite.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nisoldipine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nisoldipine.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nisoldipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Nisoldipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nisoldipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Nisoldipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nisoldipine.Approved
AtazanavirThe serum concentration of Nisoldipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nisoldipine.Approved
AtomoxetineThe metabolism of Nisoldipine can be decreased when combined with Atomoxetine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Atosiban.Approved
Atracurium besylateNisoldipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nisoldipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nisoldipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Nisoldipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Nisoldipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nisoldipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nisoldipine.Approved
BepridilNisoldipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nisoldipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Nisoldipine.Approved
BexaroteneThe serum concentration of Nisoldipine can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nisoldipine.Approved
BimatoprostNisoldipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Nisoldipine can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Nisoldipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nisoldipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nisoldipine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nisoldipine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nisoldipine.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nisoldipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Nisoldipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bupivacaine.Approved, Investigational
BupranololNisoldipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nisoldipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nisoldipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nisoldipine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Nisoldipine.Approved
CalciumThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nisoldipine.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Candesartan.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nisoldipine.Withdrawn
CandoxatrilNisoldipine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Captopril.Approved
CarbamazepineThe serum concentration of Nisoldipine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Carbetocin.Approved
CarbomycinThe metabolism of Nisoldipine can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nisoldipine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nisoldipine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nisoldipine.Approved
CeliprololNisoldipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nisoldipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nisoldipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nisoldipine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nisoldipine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Nisoldipine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nisoldipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nisoldipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Nisoldipine can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nisoldipine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nisoldipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nisoldipine.Approved
ClarithromycinThe serum concentration of Nisoldipine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Nisoldipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nisoldipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nisoldipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nisoldipine.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Nisoldipine.Approved
CobicistatThe serum concentration of Nisoldipine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nisoldipine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nisoldipine.Approved
ConivaptanThe serum concentration of Nisoldipine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nisoldipine.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nisoldipine.Investigational
CrizotinibThe metabolism of Nisoldipine can be decreased when combined with Crizotinib.Approved
CryptenamineNisoldipine may increase the hypotensive activities of Cryptenamine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nisoldipine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Nisoldipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideNisoldipine may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nisoldipine.Approved
DabrafenibThe serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nisoldipine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nisoldipine.Investigational
DarunavirThe serum concentration of Nisoldipine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Nisoldipine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Nisoldipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Nisoldipine.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nisoldipine.Experimental
DeferasiroxThe serum concentration of Nisoldipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nisoldipine can be decreased when combined with Delavirdine.Approved
DeserpidineNisoldipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Desflurane.Approved
DexamethasoneThe serum concentration of Nisoldipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dexmedetomidine.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Nisoldipine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nisoldipine.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nisoldipine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nisoldipine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nisoldipine.Approved
DihydralazineNisoldipine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Nisoldipine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nisoldipine.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nisoldipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nisoldipine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
DorzolamideNisoldipine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Doxazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nisoldipine.Approved, Investigational
DoxycyclineThe metabolism of Nisoldipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Nisoldipine can be decreased when combined with Dronedarone.Approved
DuloxetineNisoldipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nisoldipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nisoldipine.Approved
EfavirenzThe serum concentration of Nisoldipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nisoldipine.Approved
EfonidipineNisoldipine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nisoldipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Enalapril.Approved, Vet Approved
EnalaprilatNisoldipine may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Nisoldipine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nisoldipine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Eplerenone.Approved
EpoprostenolNisoldipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Eprosartan.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nisoldipine.Approved, Investigational
ErythromycinThe metabolism of Nisoldipine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Nisoldipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nisoldipine.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Nisoldipine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Nisoldipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Etacrynic acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nisoldipine.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nisoldipine.Approved
EtravirineThe serum concentration of Nisoldipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nisoldipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nisoldipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Felodipine.Approved, Investigational
FenoldopamNisoldipine may increase the hypotensive activities of Fenoldopam.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Nisoldipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nisoldipine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nisoldipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nisoldipine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nisoldipine.Approved
FluvoxamineThe metabolism of Nisoldipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nisoldipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nisoldipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Nisoldipine can be decreased when it is combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nisoldipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nisoldipine can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nisoldipine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nisoldipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nisoldipine.Experimental
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nisoldipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nisoldipine.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nisoldipine.Approved, Vet Approved
GuanabenzNisoldipine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nisoldipine.Approved
GuanethidineNisoldipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Nisoldipine.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nisoldipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Halothane.Approved, Vet Approved
HexamethoniumNisoldipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nisoldipine.Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Nisoldipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nisoldipine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
HydroflumethiazideNisoldipine may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Nisoldipine.Approved
IdelalisibThe serum concentration of Nisoldipine can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Nisoldipine.Approved, Investigational
ImatinibThe metabolism of Nisoldipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nisoldipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nisoldipine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Indapamide.Approved
IndenololNisoldipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Nisoldipine can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Nisoldipine.Approved, Investigational
IndoraminNisoldipine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nisoldipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nisoldipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nisoldipine.Approved, Investigational
IsavuconazoniumThe metabolism of Nisoldipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nisoldipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nisoldipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nisoldipine.Approved
ItraconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nisoldipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nisoldipine.Approved, Vet Approved
JosamycinThe metabolism of Nisoldipine can be decreased when combined with Josamycin.Approved
KetanserinNisoldipine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nisoldipine.Approved
KetoconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Nisoldipine can be decreased when combined with Kitasamycin.Experimental
LabetalolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Labetalol.Approved
LacidipineNisoldipine may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nisoldipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nisoldipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Nisoldipine.Approved, Investigational
LatanoprostNisoldipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nisoldipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nisoldipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Nisoldipine.Approved
LercanidipineNisoldipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nisoldipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Levobupivacaine.Approved
LevodopaNisoldipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Nisoldipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nisoldipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nisoldipine.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Lisinopril.Approved, Investigational
LofexidineNisoldipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nisoldipine.Approved
LopinavirThe serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Losartan.Approved
LovastatinThe metabolism of Nisoldipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nisoldipine can be decreased when it is combined with Lumacaftor.Approved
MacitentanNisoldipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineNisoldipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nisoldipine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mecamylamine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Nisoldipine.Approved, Nutraceutical, Vet Approved
MethazolamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nisoldipine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nisoldipine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nisoldipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nisoldipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nisoldipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nisoldipine.Approved, Investigational
MetyrosineNisoldipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nisoldipine.Experimental
MibefradilNisoldipine may increase the hypotensive activities of Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nisoldipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nisoldipine.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nisoldipine.Approved, Illicit
MifepristoneThe serum concentration of Nisoldipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nisoldipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Nisoldipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nisoldipine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nisoldipine.Approved
MitotaneThe serum concentration of Nisoldipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nisoldipine.Approved, Investigational
MivacuriumNisoldipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nisoldipine.Approved
ModafinilThe serum concentration of Nisoldipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nisoldipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nisoldipine.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Nisoldipine.Approved, Investigational
MoxonidineNisoldipine may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nisoldipine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nisoldipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nadolol.Approved
NafcillinThe serum concentration of Nisoldipine can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nisoldipine.Approved
NaftopidilNisoldipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nisoldipine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nisoldipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nisoldipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nisoldipine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nisoldipine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nisoldipine can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nisoldipine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Nisoldipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nifedipine.Approved
NiguldipineNisoldipine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Nisoldipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNisoldipine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nisoldipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nisoldipine.Approved
NitrendipineNisoldipine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNisoldipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nisoldipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nisoldipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nisoldipine.Approved, Vet Approved
ObinutuzumabNisoldipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nisoldipine.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Nisoldipine.Approved, Investigational
OlaparibThe metabolism of Nisoldipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Nisoldipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nisoldipine.Approved, Investigational
OmapatrilatNisoldipine may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nisoldipine.Approved
OsimertinibThe serum concentration of Nisoldipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nisoldipine.Approved
OxprenololNisoldipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Nisoldipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nisoldipine.Investigational
PalbociclibThe serum concentration of Nisoldipine can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nisoldipine.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Nisoldipine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nisoldipine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nisoldipine.Approved
PentobarbitalThe serum concentration of Nisoldipine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentoliniumNisoldipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nisoldipine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nisoldipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PhenobarbitalThe serum concentration of Nisoldipine can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineNisoldipine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PhentolamineNisoldipine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Nisoldipine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PinacidilNisoldipine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Nisoldipine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nisoldipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PolythiazideNisoldipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nisoldipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nisoldipine.Approved
PosaconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nisoldipine.Approved
PrazosinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
PrimidoneThe serum concentration of Nisoldipine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Propranolol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nisoldipine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nisoldipine.Approved
QuinineQuinine may increase the hypotensive activities of Nisoldipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nisoldipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nisoldipine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nisoldipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nisoldipine.Approved, Investigational
RapacuroniumNisoldipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nisoldipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nisoldipine.Approved
RescinnamineNisoldipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nisoldipine.Approved
RifabutinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nisoldipine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nisoldipine.Approved, Investigational
RilmenidineNisoldipine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Riociguat.Approved
RisperidoneNisoldipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Nisoldipine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabNisoldipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nisoldipine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nisoldipine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nisoldipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nisoldipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nisoldipine.Approved, Vet Approved
SaprisartanNisoldipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Nisoldipine can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Nisoldipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nisoldipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Nisoldipine.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nisoldipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nisoldipine.Approved
SiltuximabThe serum concentration of Nisoldipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nisoldipine can be increased when it is combined with Simeprevir.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nisoldipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nisoldipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nisoldipine.Approved, Investigational
SitaxentanNisoldipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nisoldipine.Approved
SolithromycinThe metabolism of Nisoldipine can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nisoldipine.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nisoldipine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nisoldipine.Experimental
SpiraprilNisoldipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Nisoldipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Nisoldipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nisoldipine.Approved
SulfisoxazoleThe metabolism of Nisoldipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nisoldipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Nisoldipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Nisoldipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nisoldipine.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nisoldipine.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nisoldipine.Approved
TelaprevirThe serum concentration of Nisoldipine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Nisoldipine can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Telmisartan.Approved, Investigational
TemocaprilNisoldipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nisoldipine.Approved
TerazosinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Terazosin.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nisoldipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nisoldipine.Approved
TerlipressinNisoldipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Nisoldipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nisoldipine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Thioridazine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nisoldipine.Approved
TiboloneNisoldipine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nisoldipine.Approved
TiclopidineThe metabolism of Nisoldipine can be decreased when combined with Ticlopidine.Approved
TicrynafenNisoldipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nisoldipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nisoldipine.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Nisoldipine.Approved
TocilizumabThe serum concentration of Nisoldipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineNisoldipine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nisoldipine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Nisoldipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nisoldipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nisoldipine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nisoldipine.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Nisoldipine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nisoldipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nisoldipine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nisoldipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nisoldipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nisoldipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nisoldipine.Approved
TrichlormethiazideNisoldipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinNisoldipine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanNisoldipine may increase the hypotensive activities of Trimethaphan.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nisoldipine.Approved, Investigational
TroleandomycinThe metabolism of Nisoldipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Nisoldipine can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nisoldipine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nisoldipine.Approved
UnoprostoneNisoldipine may increase the hypotensive activities of Unoprostone.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nisoldipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nisoldipine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nisoldipine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Nisoldipine.Approved
VenlafaxineThe metabolism of Nisoldipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Nisoldipine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nisoldipine.Approved, Investigational
VinpocetineNisoldipine may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Nisoldipine.Approved
VoriconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Voriconazole.Approved, Investigational
XylometazolineNisoldipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nisoldipine.Approved, Vet Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Nisoldipine.Approved
ZiprasidoneThe metabolism of Nisoldipine can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Do not take with grapefruit juice as this has been shown to interfere with nisoldipine metabolism, resulting in a mean increase in Cmax of about 3-fold (up to about 7-fold) and AUC of almost 2-fold (up to 5-fold).
References
Synthesis Reference

Massimo Ferrari, Marcello Ghezzi, Manuel Alberelli, Alberto Ambrosini, “Industrial process for the synthesis of isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate (nisoldipine).” U.S. Patent US20050240022, issued October 27, 2005.

US20050240022
General References
  1. Mielcarek J, Grobelny P, Szamburska O: The effect of beta-carotene on the photostability of nisoldipine. Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):167-71. [PubMed:15834448 ]
  2. Missan S, Zhabyeyev P, Dyachok O, Jones SE, McDonald TF: Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine. Br J Pharmacol. 2003 Nov;140(5):863-70. Epub 2003 Oct 6. [PubMed:14530219 ]
  3. Hamilton SF, Houle LM, Thadani U: Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure. Heart Dis. 1999 Nov-Dec;1(5):279-88. [PubMed:11720635 ]
External Links
ATC CodesC08CA07
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9357
Blood Brain Barrier-0.947
Caco-2 permeable+0.6928
P-glycoprotein substrateSubstrate0.5548
P-glycoprotein inhibitor IInhibitor0.8824
P-glycoprotein inhibitor IIInhibitor0.9239
Renal organic cation transporterNon-inhibitor0.8925
CYP450 2C9 substrateNon-substrate0.7874
CYP450 2D6 substrateNon-substrate0.8929
CYP450 3A4 substrateSubstrate0.7366
CYP450 1A2 substrateInhibitor0.8782
CYP450 2C9 inhibitorInhibitor0.7826
CYP450 2D6 inhibitorNon-inhibitor0.9141
CYP450 2C19 inhibitorInhibitor0.7804
CYP450 3A4 inhibitorInhibitor0.8414
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8982
Ames testNon AMES toxic0.778
CarcinogenicityNon-carcinogens0.5782
BiodegradationNot ready biodegradable0.9335
Rat acute toxicity2.6277 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8882
hERG inhibition (predictor II)Non-inhibitor0.9175
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Mylan pharmaceuticals inc
  • Shionogi pharma inc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral17 mg/1
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral25.5 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral34 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral8.5 mg/1
Prices
Unit descriptionCostUnit
Sular 25.5 mg 24 Hour tablet6.84USD tablet
Sular 34 mg 24 Hour tablet6.84USD tablet
Sular 17 mg 24 Hour tablet6.48USD tablet
Sular 34 mg tablet5.64USD tablet
Sular 17 mg tablet5.17USD tablet
Nisoldipine er 30 mg tablet5.07USD tablet
Nisoldipine er 40 mg tablet5.07USD tablet
Sular 10 mg tablet5.04USD tablet
Sular 8.5 mg 24 Hour tablet5.04USD tablet
Nisoldipine er 20 mg tablet4.65USD tablet
Sular 25.5 mg tablet4.35USD tablet
Sular 8.5 mg tablet4.13USD tablet
Sular 20 mg tablet3.37USD tablet
Sular 30 mg 24 Hour tablet3.23USD tablet
Sular 40 mg 24 Hour tablet3.23USD tablet
Sular 30 mg tablet3.1USD tablet
Sular 40 mg tablet2.61USD tablet
Sular 10 mg 24 Hour tablet2.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5422123 No1995-06-062012-06-06Us
US5626874 No1994-11-302014-11-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.26MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00577 mg/mLALOGPS
logP3.63ALOGPS
logP3.06ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)5.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity105.91 m3·mol-1ChemAxon
Polarizability39.72 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hu H, Marban E: Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Mol Pharmacol. 1998 May;53(5):902-7. [PubMed:9584217 ]
  3. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638 ]
  4. Wei X, Pan S, Lang W, Kim H, Schneider T, Perez-Reyes E, Birnbaumer L: Molecular determinants of cardiac Ca2+ channel pharmacology. Subunit requirement for the high affinity and allosteric regulation of dihydropyridine binding. J Biol Chem. 1995 Nov 10;270(45):27106-11. [PubMed:7592963 ]
  5. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23